Skip to content

FOR LABORATORY RESEARCH USE ONLY — not for human or veterinary use, diagnosis, treatment, or cosmetic application. Buyers must be 21+ and legally permitted to purchase research chemicals in their jurisdiction.Intended-use statement →

Retatrutide Wholesale

Triple receptor agonist — the next frontier in multi-pathway metabolic research

Product Identity

CAS Number2381089-83-2
Amino Acids39 residues
Molecular Weight~4,845.5 Da
LinkerC20 Fatty Diacid
Receptor TargetsGIPR · GLP-1R · GCGR
AppearanceWhite to off-white lyophilized powder
Purity≥99% by HPLC
Storage2–8°C, desiccated, protect from light
Retatrutide research peptide vialFactory-direct
Shenzhen, China

Available Configurations

ConfigurationContentBest For
Standard Kit5 mg × 10 vialsStandard research format
Bulk Kit10 mg × 10 vialsHigher-dose configuration
Extended Kit15 mg × 10 vialsExtended research format
CustomCustom mg × custom vialsOEM; private-label

Research Background

Retatrutide is a 39-amino acid single-chain peptide engineered with balanced triple agonism at GIP, GLP-1, and glucagon receptors. The addition of GCGR agonism — driving energy expenditure through thermogenesis and lipolysis — distinguishes Retatrutide from dual agonists. A C20 fatty diacid linker provides albumin binding for extended half-life, enabling sustained triple-receptor engagement from a single molecule.

Proposed Mechanisms

GIPR AgonismEnhanced insulin sensitivity and lipid buffering in white adipose tissue
GLP-1R AgonismStrong CNS-mediated appetite suppression; glucose-dependent insulin secretion
GCGR AgonismThermogenesis and lipolysis via hepatic FGF21 and direct adipocyte signaling
C20 Fatty Diacid LinkerAlbumin-binding for extended half-life while maintaining balanced triple-receptor activity

Research Focus Areas

Energy Expenditure

GCGR component uniquely boosts thermogenesis — absent in GLP-1-only agents

Body Weight

~24% mean reduction at maximum research doses — triple-receptor mediated

Glucose Homeostasis

Triple-redundant glucose control via GIPR insulin sensitivity, GLP-1R insulin secretion, GCGR hepatic output

Lipid Metabolism

Coordinated lipid mobilization across WAT lipolysis (GCGR) and lipid buffering (GIPR)

Quality Specifications

ParameterMethodCriterion
PurityRP-HPLC, C18 column, 220nm≥99.0%
IdentityESI-MSMW match within ±1 Da
Peptide ContentAmino Acid Analysis80–90% (net peptide)
Acylation FidelityLC-MSConfirmed C20 diacid conjugation
Water ContentKarl Fischer≤8%
Trifluoroacetate (TFA)Ion Chromatography≤1%
AppearanceVisualWhite to off-white lyophilized powder

Tiered Wholesale Pricing

Kit sizeCodeList price
10 mg × 10 vialsRT10US$58
15 mg × 10 vialsRT15US$79
20 mg × 10 vialsRT20US$101
30 mg × 10 vialsRT30US$138
40 mg × 10 vialsRT40US$185
50 mg × 10 vialsRT50US$233
60 mg × 10 vialsRT60US$259

US$58–259 per kit (10 vials), from our published wholesale price list; tiered volume discounts apply (see the tier table) — source:wholesale price list (PDF, updated 2026-08-08).

VolumeDiscountFor
1 kitList priceEvaluation; competitive analysis
5+ kits10% offInitial portfolio expansion
20+ kits20% offMid-size distributors
50+ kits30% offRegional distributors

FAQ

What is the difference between Retatrutide and Tirzepatide?

Retatrutide adds a third receptor target — the glucagon receptor (GCGR) — to the GIP/GLP-1 dual agonism of Tirzepatide. The glucagon component drives increased energy expenditure and lipolysis. Published data show ~24% body weight reduction with Retatrutide compared to ~21% with Tirzepatide at maximum research doses.

Why is Retatrutide more difficult to manufacture?

Retatrutide's complexity arises from engineering balanced triple-receptor agonism into a single 39-amino-acid peptide. Achieving the correct potency ratio across GIP, GLP-1, and glucagon receptors requires precise amino acid substitutions and the C20 fatty diacid linker. Each receptor's activation profile must be tuned so that none dominates or is suppressed.

How should Retatrutide be reconstituted for research?

Retatrutide is supplied as a lyophilized powder and is typically reconstituted in bacteriostatic water or sterile buffer at your laboratory's validated concentration. Full solubility data is included in the batch-specific COA. After reconstitution, use within your protocol-validated timeframe.

Can I order Retatrutide with private labeling?

Yes. We offer OEM/private-label services for Retatrutide with custom vial branding, labeling, and packaging. Minimum order quantities apply for private-label runs. Contact Dr. Aaron Wang for a private-label quotation including lead times, artwork specifications, and MOQ details.

All products are manufactured for laboratory research purposes only. Retatrutide is labeled FOR LABORATORY RESEARCH USE ONLY. Not for human or veterinary use, diagnosis, treatment, prophylaxis or any clinical, cosmetic, dietary or household application. Not a dietary supplement, pharmaceutical ingredient, cosmetic ingredient or approved drug substance. Buyers are responsible for verifying the legal status of importation and possession in their destination country. Incretin analogues are prescription or investigational substances in many jurisdictions — buyers must confirm the legal status of importation and possession, and hold any required authorisation.

Ready to Source Third-Generation Metabolic Peptides?

Triple agonism, batch-traceable, ≥99% purity. Contact Dr. Aaron Wang for pricing and availability.

← Back to Metabolic